Abstract: The present disclosure relates to methods of initiating brexpiprazole treating in patients with schizophrenia or major depressive disorder. The present disclosure further relates to modified dosing regimens for obese patients and/or patients that are CYP2D6 poor metabolizers. In embodiments, the modified dosing regimens administers double the daily dose while initiating treatment.
Type:
Grant
Filed:
January 13, 2022
Date of Patent:
April 9, 2024
Assignee:
LAKE O'HARA LLC
Inventors:
Sundar Srinivasan, Christina Chow Wallen
Abstract: The present disclosure relates to methods of initiating brexpiprazole treating in patients with schizophrenia or major depressive disorder. The present disclosure further relates to modified dosing regimens for obese patients and/or patients that are CYP2D6 poor metabolizers. In embodiments, the modified dosing regimens administers double the daily dose while initiating treatment.
© 2024 Justia
